Bubendorf/Basel, March 21, 2014 – Bachem Group (SIX: BANB), the market leader in the field of peptide chemistry with a distinctive focus on quality and innovation, generated sales of 170.7 million CHF in 2013 (2012: 157.3 million CHF, +8.5% in CHF and +8.9% in local currency/LC) in the face of persisting challenges in the market. The research ingredients activities made significant progress in 2013. Generics sales slightly fell short of expectations while the business with patented substances (NCEs), a bellwether of the company’s future sales, experienced brisk growth. Bachem was able to further expand its market leadership in this segment. Thanks to cost savings, further efficiency gains and a focus on the core business, Bachem increased its operating profit (EBIT) by +31.9% to 29.5 million CHF. The EBITDA margin rose to 27.8% and the EBIT margin to 17.3%. Bachem achieved another strong increase in net income which surged by 51.7% to 23.6 million CHF. Bachem intends to grow its top and bottom line steadily during the years ahead.